Palvella Therapeutics, Inc.
PVLA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583648
In the last 90 days, Palvella Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 196 institutions reported holding it in 13F filings for Q2 2026, worth $2.15B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $2.54B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $9.64M in total
- 6
- 13F holdersQ2 2026, +18 vs. previous quarter
- 196
- 13F valueReported value at the end of Q2 2026
- $2.15B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$41.7M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 2.41M
- Shares sold short
- Change
- −116.7K
- −4.6% vs. previous
- Days to cover
- 9.83
- At average daily volume
Superinvestors holding PVLA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding PVLA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Palvella Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 23, 2026 (view filing)4:05 PM ET | Oct 21 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.31K | $124.58 | −$537.3K | −100.0%0 after | 3 lots10b5-1 |
| Oct 14, 2026 (view filing)7:14 PM ET | Oct 12-14 | 2 days | Jenkins George MDirector | SSale | −27.5K | $130.16 | −$3.58M | −17.2%132.6K after | 17 lots10b5-1 |
| Sep 18, 2026 (view filing)4:05 PM ET | Sep 16 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $152.24 | −$654.9K | −100.0%0 after | 3 lots10b5-1 |
| Sep 15, 2026 (view filing)9:15 PM ET | Sep 11-15 | 4 days | Jenkins George MDirector | SSale | −27.5K | $151.53 | −$4.17M | −14.7%160.1K after | 9 lots10b5-1 |
| Sep 4, 2026 (view filing)4:05 PM ET | Sep 2 | 2 days | Kiritsy Christopher PDirector | SSale | −313 | $157.00 | −$49.1K | −55.6%250 after | |
| Aug 20, 2026 (view filing)4:05 PM ET | Aug 19 | 1 day | Goin KathleenChief Operating Officer | SSale | −4.30K | $152.21 | −$654.8K | −100.0%0 after | 5 lots10b5-1 |
| Jul 17, 2026 (view filing)4:05 PM ET | Jul 15 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $149.28 | −$642.2K | −100.0%0 after | 4 lots10b5-1 |
| Jun 22, 2026 (view filing) | Jun 17 | 5 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $110.73 | −$476.4K | −100.0%0 after | 3 lots10b5-1 |
| May 22, 2026 (view filing) | May 20 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $110.56 | −$475.6K | −100.0%0 after | 3 lots10b5-1 |
| Apr 17, 2026 (view filing) | Apr 15 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $127.24 | −$547.4K | −100.0%0 after | 5 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 196 holdersThe largest institutional positions in Palvella Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 1,135,406 | $173.5M | 3.65% | −18,090−1.6% | Reduced |
| Jennison Associates LLC | 960,619 | $146.8M | 0.09% | +320,008+50.0% | Added |
| BlackRock, Inc. | 918,357 | $140.3M | 0.00% | +231,504+33.7% | Added |
| Frazier Life Sciences Management, L.P. | 882,400 | $134.8M | 2.94% | 00.0% | Unchanged |
| First Light Asset Management, LLC | 771,901 | $118.0M | 7.17% | −208,857−21.3% | Reduced |
| BVF Inc | 672,789 | $102.8M | 2.63% | −288,200−30.0% | Reduced |
| State Street Corp | 653,172 | $99.8M | 0.00% | +194,173+42.3% | Added |
| Price T Rowe Associates Inc | 638,868 | $97.6M | 0.01% | +236,304+58.7% | Added |
| Vanguard Capital Management LLC | 513,794 | $78.5M | 0.00% | +36,500+7.6% | Added |
| Frontier Capital Management Co LLC | 478,833 | $73.2M | 0.68% | +104,798+28.0% | Added |
Holders of 5% or more of PVLA
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Palvella Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Kaupinen Wes | 13D | 14.60%1.64M shares | New | Dec 20, 20241 filing | Dec 20, 2024 | SEC |
| Jennison Associates LLC | 13G/A | 7.70%1.10M shares | +1.00 ppfrom 6.70% | Aug 3, 20262 filings | Oct 28, 2026 | SEC |
| Suvretta Capital Management, LLC | 13G/A | 7.40%822.4K shares | −1.20 ppfrom 8.60% | Dec 20, 20242 filings | Nov 13, 2025 | SEC |
| Prudential Financial Inc | 13G | 6.70%962.4K shares | New | Aug 10, 20261 filing | Aug 10, 2026 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 6.00%706.4K shares | +1.10 ppfrom 4.90% | Jan 8, 20254 filings | Feb 13, 2026 | SEC |